Global biopharmaceutical services organization,
PAREXEL International Corporation
) launched a new version of its industry standard ClinPhone RTSM
(Randomization and Trial Supply Management) solution designed to
help start clinical trials more quickly. Following the
announcement, shares of PAREXEL climbed 2.2% to close at $53.67
The latest version of the ClinPhone RTSM solution has been
developed by PAREXEL Informatics - PAREXEL's wholly owned
technology subsidiary, which acquired ClinPhone Plc - a clinical
technology organization, in 2008.
At the start of a clinical trial, clients have to simultaneously
initiate a broad range of important activities such as patient
screening, enrollment and randomization, drug dispensation and
supply distribution. PAREXEL's ClinPhone RTSM is incorporated with
flexible, pre-built and interactive web modules that allow rapid
implementation of patient, supplies and site management activities.
As part of the ClinPhone RTSM solution, its web modules provide
extended functionality and place increased administrative and
management control in the hands of the study teams. Integrated with
the latest RTSM technology that features standardized study
components for faster implementation and greater design
flexibility, the study teams can start their trials more quickly.
RTSM solution is a key component of PAREXEL's proprietary
Perceptive MyTrials platform, an integrated suite of applications
for managing clinical trials. The leading edge solution has been
used in more than 3,000 studies involving over 400,000 sites and
two million patients since 1993.
PAREXEL's ClinPhone RTSM is available as a standalone solution as
well as through the Perceptive MyTrials platform. ClinPhone RTSM
and the Perceptive MyTrials platform are also available through the
company's Perceptive Partner Program.
PAREXEL intends to meet the increasing need for conducting faster
and more efficient trials by making considerable investments in
developing cutting-edge technology. It is also focusing on making
drug development more efficient, without compromising on patient
safety or data quality.
Currently, PAREXEL has a Zacks Rank #3 (Hold). Better-ranked stocks
in the medical services industry include
ICON Public Limited Company
BG Medicine, Inc.
). While ICON Public Limited Company sports a Zacks Rank #1 (Strong
Buy), both BG Medicine and Omnicare carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
OMNICARE INC (OCR): Free Stock Analysis Report
PAREXEL INTL CP (PRXL): Free Stock Analysis
ICON PLC (ICLR): Free Stock Analysis Report
BG MEDICINE INC (BGMD): Free Stock Analysis
To read this article on Zacks.com click here.